Hangzhou Tigermed Consulting Co., Ltd. (abbreviated “TIGERMED”) has released an updated version of its Articles of Association, dated March 2026. The document clarifies key details regarding corporate framework, operational scope, governance mechanisms, and shareholder rights. Registered capital stands at RMB861.03 million, and the company identifies itself as a joint stock limited entity conducting medical research, data processing, and various technology services.

According to the document, the Company’s total share capital comprises 861.03 million shares, with 85.70% held as domestic shares and 14.30% as H shares. Shareholders are granted rights to participate and vote at general meetings, with the board of directors comprising seven members, including three independent directors and one representative from the workforce. The Articles detail compliance obligations, rules for convening general meetings, and procedures for major decisions such as mergers, capital adjustments, and profit distribution.

A notable emphasis is placed on committees under the board of directors, especially the audit committee. The committee, which includes independent directors, holds responsibilities such as examining financial disclosures and supervising internal audits. The governance framework also features provisions on director and senior management conduct, detailing measures on external guarantees, conflict of interest management, and procedures for potential company reorganizations or dissolutions.

This comprehensive structure aims to reinforce effective governance, protect shareholder interests, and maintain stringent financial oversight, underscoring the Company’s commitment to transparent management in accordance with legal and regulatory requirements.